A Randomised, Open Label Study to Investigate the Impact of Bone Marker Feedback at 2 Months on Adherence to Monthly Oral Bonviva (Ibandronate) in Women With Post-menopausal Osteoporosis
Phase of Trial: Phase IV
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms BEATRIS
- Sponsors Roche
- 17 Sep 2008 Actual end date is August 2008 as reported by ClinicalTrials.gov.
- 17 Sep 2008 Actual patient number is 585 as reported by ClinicalTrials.gov.
- 17 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.